Christy L. Lavine

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.